These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15565637)

  • 1. Thalidomide for advanced hepatocellular carcinoma: is this a real alternative?
    Wadler S
    Cancer; 2005 Jan; 103(1):1-4. PubMed ID: 15565637
    [No Abstract]   [Full Text] [Related]  

  • 2. alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma.
    Chen LT; Liu TW; Chao Y; Shiah HS; Chang JY; Juang SH; Chen SC; Chuang TR; Chin YH; Whang-Peng J
    Aliment Pharmacol Ther; 2005 Aug; 22(3):217-26. PubMed ID: 16091059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with inhibitors of angiogenesis in advanced hepatocellular carcinoma: a new tool in our hands or simply a hope?
    Cipriani G; Mazzanti R
    Dig Liver Dis; 2005 Apr; 37(4):230-1. PubMed ID: 15788205
    [No Abstract]   [Full Text] [Related]  

  • 4. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
    Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma.
    Hsu WC; Chan SC; Ting LL; Chung NN; Wang PM; Ying KS; Shin JS; Chao CJ; Lin GD
    Jpn J Clin Oncol; 2006 Feb; 36(2):93-9. PubMed ID: 16517834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute tumor lysis syndrome after thalidomide therapy in advanced hepatocellular carcinoma.
    Lee CC; Wu YH; Chung SH; Chen WJ
    Oncologist; 2006 Jan; 11(1):87-8; author reply 89. PubMed ID: 16401719
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma.
    Shiah HS; Chao Y; Chen LT; Yao TJ; Huang JD; Chang JY; Chen PJ; Chuang TR; Chin YH; Whang-Peng J; Liu TW
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):654-64. PubMed ID: 16520988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
    Yau T; Chan P; Wong H; Ng KK; Chok SH; Cheung TT; Lam V; Epstein RJ; Fan ST; Poon RT
    Oncology; 2007; 72 Suppl 1():67-71. PubMed ID: 18087184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide.
    Patt YZ; Hassan MM; Lozano RD; Ellis LM; Peterson JA; Waugh KA
    Am J Clin Oncol; 2000 Jun; 23(3):319-21. PubMed ID: 10857902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latest developments in targeted therapy for hepatocellular carcinoma.
    Montella L; Addeo R; Caraglia M; Del Prete S
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1635-46. PubMed ID: 20942634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic strategies in hepatocellular carcinoma: current status.
    Zacharoulis D; Hatzitheofilou C; Athanasiou E; Zacharoulis S
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):645-56. PubMed ID: 16111465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose thalidomide treatment for advanced hepatocellular carcinoma.
    Hsu C; Chen CN; Chen LT; Wu CY; Yang PM; Lai MY; Lee PH; Cheng AL
    Oncology; 2003; 65(3):242-9. PubMed ID: 14657598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenesis and anti-angiogenesis in hepatocellular carcinoma.
    Ribatti D; Vacca A; Nico B; Sansonno D; Dammacco F
    Cancer Treat Rev; 2006 Oct; 32(6):437-44. PubMed ID: 16870349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hypoxia in hepatocellular carcinoma].
    Myung SJ; Yoon JH
    Korean J Hepatol; 2007 Mar; 13(1):9-19. PubMed ID: 17380070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma.
    Chuah B; Lim R; Boyer M; Ong AB; Wong SW; Kong HL; Millward M; Clarke S; Goh BC
    Acta Oncol; 2007; 46(2):234-8. PubMed ID: 17453375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
    Cappa FM; Cantarini MC; Magini G; Zambruni A; Bendini C; Santi V; Bernardi M; Trevisani F
    Dig Liver Dis; 2005 Apr; 37(4):254-9. PubMed ID: 15788209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful targeted therapies for hepatocellular carcinoma: are we really getting there?
    Zhu AX
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):499-505. PubMed ID: 18402516
    [No Abstract]   [Full Text] [Related]  

  • 18. Dramatic reduction in tumour size in hepatocellular carcinoma patients on thalidomide therapy.
    Demeria D; Birchall I; Bain VG
    Can J Gastroenterol; 2007 Aug; 21(8):517-8. PubMed ID: 17703252
    [No Abstract]   [Full Text] [Related]  

  • 19. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.
    Patt YZ; Hassan MM; Lozano RD; Nooka AK; Schnirer II; Zeldis JB; Abbruzzese JL; Brown TD
    Cancer; 2005 Feb; 103(4):749-55. PubMed ID: 15660400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalidomide-induced severe facial erythema in a patient with hepatocellular carcinoma.
    Chiou CC; Shih IH; Chang YC; Lee JC; Kuo SC; Hong HS; Yang CH
    Int J Clin Pract; 2007 Aug; 61(8):1415-7. PubMed ID: 17627717
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.